BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Letrozole readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Letrozole\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06974929-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT06974929)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Clinical Study of HRS-6209 Combined With Other Treatment Regimens i
 n Patients With Breast Cancer\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06974929
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05997017-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase 2 readout est. (NCT05997017)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Trial of Nab-Sirolimus in Combinat
 ion With Letrozole in Patients With Advanced or Recurrent Endometrioid End
 ometrial Cancer\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05997017
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05780567-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase 3 readout est. (NCT05780567)
DESCRIPTION:Letrozole\, phase 3.\nStudy: Clinical Study on Adjuvant Therapy
  of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined
  With Endocrine Therapy in Patients With Breast Cancer\nEstimated primary 
 completion: December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05780567
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04486911-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Letrozole: Phase 2 readout est. (NCT04486911)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Pyrotinib Maleate\, CDK4/6 Inhibit
 or and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial\nE
 stimated primary completion: 1 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04486911
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04393285-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Letrozole: Phase 2 readout est. (NCT04393285)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Abemaciclib and Letrozole to Treat
  Endometrial Cancer\nEstimated primary completion: 1 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04393285
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04886531-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Letrozole: Phase 2 readout est. (NCT04886531)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab
  in ER-Positive\, HER-2 Positive Breast Cancers\nEstimated primary complet
 ion: 22 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04886531
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03006172-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase 1 readout est. (NCT03006172)
DESCRIPTION:Letrozole\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: To Evaluate the Safety\, Tolerability\, and Pharmacokinetics of Inavoli
 sib Single Agent in Participants With Solid Tumors and in Combination With
  Endocrine and Targeted Therapies in Participants With Breast Cancer\nEsti
 mated primary completion: 31 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03006172
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04553133-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase 2 readout est. (NCT04553133)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: PF-07104091 as a Single Agent and in Combination Therapy\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04553133
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05286437-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase 2 readout est. (NCT05286437)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Can
 cer With Letrozole\nEstimated primary completion: 31 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05286437
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06354439-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase 4 readout est. (NCT06354439)
DESCRIPTION:Letrozole\, phase 4.\nStudy: Use of Letrozole for Ectopic Pregn
 ancy\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06354439
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05487092-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letrozole: Phase na readout est. (NCT05487092)
DESCRIPTION:Letrozole\, phase na.\nStudy: Letrozole in Preventing Recurrenc
 e of Endometrioma Following Laparoscopic Ovarian Cystectomy\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05487092
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02562118-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT02562118)
DESCRIPTION:Letrozole\, phase 1/2.\nStudy: Neoadjuvant Lenvatinib Combined 
 With Letrozole in Hormone Receptor Positive Breast Cancer\nEstimated prima
 ry completion: January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT02562118
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767435-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT07767435)
DESCRIPTION:Letrozole\, phase 1/2.\nStudy: Second Trimester Abortion With L
 etrozole and Misoprostol Compared to Misoprostol Alone\nEstimated primary 
 completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07767435
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Letrozole: Phase 3 readout est. (NCT04906395)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breas
 t Cancer\nEstimated primary completion: 30 January 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425990-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Letrozole: Phase na readout est. (NCT07425990)
DESCRIPTION:Letrozole\, phase na.\nStudy: FET-LET-2x2: Clinical Pregnancy R
 ates After Frozen Embryo Transfer in Natural and Modified Natural Cycles\n
 Estimated primary completion: February 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07425990
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04095364-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Letrozole: Phase 3 readout est. (NCT04095364)
DESCRIPTION:Letrozole\, phase 3.\nStudy: Letrozole With or Without Paclitax
 el and Carboplatin in Treating Patients With Stage II-IV Ovarian\, Fallopi
 an Tube\, or Primary Peritoneal Cancer\nEstimated primary completion: 1 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozol
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 095364
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05262400-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT05262400)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Study to Learn About the Study Medicine (Called PF-07220060 in Comb
 ination With PF-07104091) In Participants With Breast Cancer and Solid Tum
 ors\nEstimated primary completion: 26 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05262400
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01872260-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT01872260)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of LEE011\, BYL719 and Letrozole in Advanced ER+ Breast Cancer\
 nEstimated primary completion: 26 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT01872260
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07305246-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Letrozole: Phase 2 readout est. (NCT07305246)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Clinical Study of SHR-A1811 With o
 r Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive\, H
 ER2-Low Breast Cancer\nEstimated primary completion: March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07305246
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Letrozole: Phase 2 readout est. (NCT06179303)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Functional Imaging in Prediction of Response to Abemaciclib for Advance
 d Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEstimated prima
 ry completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06179303
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753655-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Letrozole: Phase na readout est. (NCT07753655)
DESCRIPTION:Letrozole\, phase na.\nStudy: The Value of Pretreatment With Le
 trozole on Induction Time of Medical Evacuation With Misoprostol in Cases 
 of Missed Abortion\nEstimated primary completion: 1 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07753655
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05247268-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270310
DTEND;VALUE=DATE:20270311
SUMMARY:Letrozole: Phase 2 readout est. (NCT05247268)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Gonadotropin-releasing Hormone Ago
 nist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer\n
 Estimated primary completion: 10 March 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05247268
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923214-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Letrozole: Phase 1 readout est. (NCT07923214)
DESCRIPTION:Letrozole\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination T
 herapy in Advanced Solid Tumors\nEstimated primary completion: April 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07923214
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06394804-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Letrozole: Phase 2 readout est. (NCT06394804)
DESCRIPTION:Letrozole\, phase 2.\nStudy: A Study of Avutometinib\, Defactin
 ib\, and Letrozole in People With Low-Grade Serous Ovarian Cancer\nEstimat
 ed primary completion: April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06394804
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05464810-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Letrozole: Phase 1 readout est. (NCT05464810)
DESCRIPTION:Letrozole\, phase 1.\nStudy: Letrozole With and Without Simvast
 atin for the Treatment of Stage I-III Hormone Receptor Positive\, HER2 Neg
 ative Breast Cancer\nEstimated primary completion: 15 April 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05464810
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04614194-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Letrozole: Phase 2 readout est. (NCT04614194)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Single Cell Immune and Non-immune 
 Correlates of Response to Neoadjuvant Abemaciclib\nEstimated primary compl
 etion: 15 April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04614194
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05900206-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Letrozole: Phase 2 readout est. (NCT05900206)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Trastuzumab Deruxtecan Versus Stan
 dard Neoadjuvant Treatment for HER2-positive Breast Cancer\nEstimated prim
 ary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/letrozole#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05900206
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07065539-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Letrozole: Phase na readout est. (NCT07065539)
DESCRIPTION:Letrozole\, phase na.\nStudy: GnRH Agonist Pretreatment Duratio
 n and Letrozole Supplementation in Frozen Embryo Transfer for Adenomyosis 
 Patients\nEstimated primary completion: May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07065539
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624903-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Letrozole: Phase 2 readout est. (NCT07624903)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Letrozole Versus Methotrexate for 
 Management of Undisturbed Ectopic Pregnancy\nEstimated primary completion:
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 24903
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07394946-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Letrozole: Phase 2 readout est. (NCT07394946)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Neoadjuvant Letrozole in Postmenop
 ausal Women With Hormone Receptor-Positive\, HER2-Negative\, Node Positive
 \, Early-Stage Breast Cancer.\nEstimated primary completion: July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07394946
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04469764-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Letrozole: Phase 2 readout est. (NCT04469764)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Abemaciclib for the Treatment of R
 ecurrent Ovarian or Endometrial Cancer\nEstimated primary completion: 1 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT044697
 64
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029399-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Letrozole: Phase 1 readout est. (NCT07029399)
DESCRIPTION:Letrozole\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors\n
 Estimated primary completion: 31 July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07029399
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054190-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Letrozole: Phase 2 readout est. (NCT07054190)
DESCRIPTION:Letrozole\, phase 2.\nStudy: A Study to Test Inavolisib Treatme
 nts in Participants With Early-Stage\, PIK3CA-Mutated Breast Cancer\nEstim
 ated primary completion: 31 July 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07054190
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05181033-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Letrozole: Phase 2 readout est. (NCT05181033)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast 
 Cancer\, Post Progression on Al + CDK4/6 Inhibitor\nEstimated primary comp
 letion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05181033
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03122197-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Letrozole: Phase 1 readout est. (NCT03122197)
DESCRIPTION:Letrozole\, phase 1.\nStudy: Study of Letrozole in Recurrent Gl
 iomas\nEstimated primary completion: 1 September 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03122197
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06366347-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Letrozole: Phase 2 readout est. (NCT06366347)
DESCRIPTION:Letrozole\, phase 2.\nStudy: ALPINE: Maintenance Letrozole/Abem
 aciclib\nEstimated primary completion: 1 September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06366347
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06913075-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Letrozole: Phase na readout est. (NCT06913075)
DESCRIPTION:Letrozole\, phase na.\nStudy: FET in Adenomyosis\nEstimated pri
 mary completion: 15 September 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06913075
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06650748-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Letrozole: Phase 2 readout est. (NCT06650748)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Multigene Risk Score Combined With
  Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Trea
 tment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer\nEstima
 ted primary completion: 1 October 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06650748
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04563507-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Letrozole: Phase 2 readout est. (NCT04563507)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Combined Immunotherapies in Metastatic ER+ Breast Cancer\nEstimated pri
 mary completion: 31 October 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04563507
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979596-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:Letrozole: Phase 2 readout est. (NCT06979596)
DESCRIPTION:Letrozole\, phase 2.\nStudy: A Study of MK-5684 in People With 
 Certain Solid Tumors (MK-5684-015/OMAHA-015)\nEstimated primary completion
 : 4 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/le
 trozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06979596
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555068-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT06555068)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Trial of HRS-6209 in Combination With Other Antitumor Therapies in 
 Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advance
 d Solid Tumors\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06555068
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935317-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Letrozole: Phase 2 readout est. (NCT07935317)
DESCRIPTION:Letrozole\, phase 2.\nStudy: A Study of Tersolisib (LY4064809) 
 and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated
  Early Breast Cancer\nEstimated primary completion: December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07935317
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06733727-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271205
DTEND;VALUE=DATE:20271206
SUMMARY:Letrozole: Phase na readout est. (NCT06733727)
DESCRIPTION:Letrozole\, phase na.\nStudy: Letrozole Versus Mifepristone and
  Misoprostol in Silent Miscarriage\nEstimated primary completion: 5 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067337
 27
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014410-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Letrozole: Phase 2 readout est. (NCT07014410)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-posit
 ive and HER2-positive Advanced Breast Cancer\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/l
 etrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07014410
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285382-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Letrozole: Phase 2 readout est. (NCT07285382)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Different Doses of Dalpicicl Combined With Letrozole in the First-line 
 Treatment of HR-positive\, HER2-negative Advanced Breast Cancer\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07285382
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Letrozole: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Fudan University Shanghai Cancer C
 enter Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07319429-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Letrozole: Phase 2/3 readout est. (NCT07319429)
DESCRIPTION:Letrozole\, phase 2/3.\nStudy: Refining Fertility-sparing Treat
 ment in Endometrial Carcinoma Based on Molecular Classification\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07319429
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05872204-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Letrozole: Phase 2 readout est. (NCT05872204)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive R
 are Ovarian Cancer\nEstimated primary completion: January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05872204
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691333-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Letrozole: Phase 2 readout est. (NCT07691333)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Kumorixilib Plus Capecitabine and 
 Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Ca
 ncer\nEstimated primary completion: 30 January 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07691333
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of AVZO-021 in Patients With Advanced Solid Tumors\nEstimated p
 rimary completion: 31 January 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04111978-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Letrozole: Phase 3 readout est. (NCT04111978)
DESCRIPTION:Letrozole\, phase 3.\nStudy: MAintenance Therapy With Aromatase
  Inhibitor in Epithelial Ovarian Cancer (MATAO)\nEstimated primary complet
 ion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04111978
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Letrozole: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Letrozole\, phase 2.\nStudy: A Study Evaluating the Efficacy an
 d Safety of Biomarker-Driven Therapies in Patients With Persistent or Recu
 rrent Rare Epithelial Ovarian Tumors\nEstimated primary completion: 28 Feb
 ruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT049
 31342
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07676331-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Letrozole: Phase 2 readout est. (NCT07676331)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Clinical Study of Local and System
 ic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast
  Cancer: The CLARA Trial\nEstimated primary completion: 1 March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07676331
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795424-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Letrozole: Phase 2 readout est. (NCT07795424)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Culmerciclib Combined With Letrozo
 le and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Canc
 er\nEstimated primary completion: 30 March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07795424
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05316935-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Letrozole: Phase 2/3 readout est. (NCT05316935)
DESCRIPTION:Letrozole\, phase 2/3.\nStudy: GnRHa + Letrozole in Non-obese P
 rogestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients\
 nEstimated primary completion: 30 March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05316935
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06379113-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Letrozole: Phase 2/3 readout est. (NCT06379113)
DESCRIPTION:Letrozole\, phase 2/3.\nStudy: GnRHa + Letrozole in Obese Proge
 stin-insensitive Endometrial Cancer Patients\nEstimated primary completion
 : 30 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letr
 ozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06379113
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03011684-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Letrozole: Phase 3 readout est. (NCT03011684)
DESCRIPTION:Letrozole\, phase 3.\nStudy: Fertility Preservation Using Tamox
 ifen and Letrozole in Estrogen Sensitive Tumors Trial\nEstimated primary c
 ompletion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03011684
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04568616-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280402
DTEND;VALUE=DATE:20280403
SUMMARY:Letrozole: Phase 2 readout est. (NCT04568616)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Phase II Study of Neoadjuvant ArOM
 atase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)\nEstimated primary c
 ompletion: 2 April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04568616
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07401381-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Letrozole: Phase 1 readout est. (NCT07401381)
DESCRIPTION:Letrozole\, phase 1.\nStudy: A Study to Compare the Steady-Stat
 e Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-M
 enopausal Women With Hormone Receptor Positive Early Breast Cancer\nEstima
 ted primary completion: May 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07401381
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891093-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Letrozole: Phase 3 readout est. (NCT05891093)
DESCRIPTION:Letrozole\, phase 3.\nStudy: Efficacy and Safety of Fluzoparib 
 Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early 
 Breast Cancer (BCTOP-L-A01)\nEstimated primary completion: 31 May 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05891093
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05649956-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Letrozole: Phase 2 readout est. (NCT05649956)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Letrozole in Uterine Leiomyosarcom
 a\nEstimated primary completion: 30 July 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05649956
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998407-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT06998407)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: ORION-1: Study of AVZO-023 as a Single Agent and in Combination With 
 AVZO-021\, and/or Endocrine Therapy in Advanced Solid Tumors\nEstimated pr
 imary completion: August 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/letrozole#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06998407
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03675893-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Letrozole: Phase 2 readout est. (NCT03675893)
DESCRIPTION:Letrozole\, phase 2.\nStudy: RESOLVE: Abemaciclib + Letrozole +
 /- Metformin or Gedatolisib in Endometrial Cancer\nEstimated primary compl
 etion: 1 August 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03675893
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900516-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Letrozole: Phase 2 readout est. (NCT07900516)
DESCRIPTION:Letrozole\, phase 2.\nStudy: A Prospective\, Phase II\, Explora
 tory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combi
 nation Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.\nEstima
 ted primary completion: 1 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07900516
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05467891-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Letrozole: Phase 2 readout est. (NCT05467891)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregion
 al Recurrent\, Resected Hormone Receptor Positive HER2 Negative Breast Can
 cer\nEstimated primary completion: 15 August 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05467891
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03008408-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Letrozole: Phase 2 readout est. (NCT03008408)
DESCRIPTION:Letrozole\, phase 2.\nStudy: A Phase II\, Two-Arm Study of Ever
 olimus and Letrozole\, +/- Ribociclib (Lee011) in Patients With Advanced o
 r Recurrent Endometrial Carcinoma\nEstimated primary completion: 31 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03008408
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143631-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280911
DTEND;VALUE=DATE:20280912
SUMMARY:Letrozole: Phase 4 readout est. (NCT06143631)
DESCRIPTION:Letrozole\, phase 4.\nStudy: Prescription of Letrozole for Uter
 ine Myoma\nEstimated primary completion: 11 September 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06143631
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07801898-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Letrozole: Phase 2 readout est. (NCT07801898)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Neoadjuvant Endocrine Therapy Comb
 ined With Chemotherapy in ER-positive\, HER2-negative Stage I-III Breast C
 ancer\nEstimated primary completion: 30 September 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07801898
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389733-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT07389733)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Study of HRS-6208 in Combination With HRS-8080\, or Fulvestrant\, o
 r Letrozole\, With or Without HRS-6209 in Patients With Advanced Unresecta
 ble or Metastatic Breast Cancer\nEstimated primary completion: December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07389733
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05035836-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:Letrozole: Phase 2 readout est. (NCT05035836)
DESCRIPTION:Letrozole\, phase 2.\nStudy: A Phase 2 Single-Arm Open-Label Pi
 lot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/
 Neu Positive (HER2+) Breast Cancer (BC)\nEstimated primary completion: 29 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letroz
 ole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05035836
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760637-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Letrozole: Phase 3 readout est. (NCT06760637)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-neg
 ative Breast Cancer Who Have Not Received Anticancer Treatment for Advance
 d/Metastatic Disease\nEstimated primary completion: 2 January 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06760637
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340658-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Letrozole: Phase 3 readout est. (NCT07340658)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Study to Investigate the Efficacy and Safety of Letrozole SIE Compare
 d With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Po
 stmenopausal Women With HR-Positive\, HER2-Negative\, Inoperable Locally A
 dvanced or Metastatic Breast Cancer\nEstimated primary completion: Februar
 y 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0734065
 8
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757634-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Letrozole: Phase 3 readout est. (NCT06757634)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With 
 HR-Positive\, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)\nEstimated
  primary completion: 31 March 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06757634
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492641-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Letrozole: Phase 3 readout est. (NCT07492641)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients Wit
 h Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Pri
 or Treatment for Advanced or Metastatic Disease\nEstimated primary complet
 ion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letr
 ozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07492641
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07508657-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Letrozole: Phase 4 readout est. (NCT07508657)
DESCRIPTION:Letrozole\, phase 4.\nStudy: Progesterone Supplementation After
  Letrozole-stimulated Insemination\nEstimated primary completion: June 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07508657
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061717-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Letrozole: Phase 3 readout est. (NCT07061717)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hyd
 roxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbocicl
 ib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer\
 nEstimated primary completion: 1 July 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07061717
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391774-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Letrozole: Phase 3 readout est. (NCT07391774)
DESCRIPTION:Letrozole\, phase 3.\nStudy: Testing Whether Hormone Therapy Wi
 th Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy 
 With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer Wit
 h Low Recurrence Risk\, The RxFINE-Low Trial\nEstimated primary completion
 : 31 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letro
 zole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07391774
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492616-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Letrozole: Phase 3 readout est. (NCT06492616)
DESCRIPTION:Letrozole\, phase 3.\nStudy: A Study of Elacestrant Versus Stan
 dard Endocrine Therapy in Women and Men With ER+\,HER2-\, Early Breast Can
 cer With High Risk of Recurrence\nEstimated primary completion: August 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06492616
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Letrozole: Phase 2 readout est. (NCT04606446)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Study of PF-07248144 in Advanced or Metastatic Solid Tumors\nEstimated 
 primary completion: 27 August 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827081-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Letrozole: Phase 3 readout est. (NCT05827081)
DESCRIPTION:Letrozole\, phase 3.\nStudy: Phase IIIb Study of Ribociclib + E
 T in Early Breast Cancer\nEstimated primary completion: 7 September 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05827081
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05601700-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20290922
DTEND;VALUE=DATE:20290923
SUMMARY:Letrozole: Phase 3 readout est. (NCT05601700)
DESCRIPTION:Letrozole\, phase 3.\nStudy: Letrozole for Estrogen/Progesteron
 e Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Tria
 l)\nEstimated primary completion: 22 September 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05601700
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557449-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20291007
DTEND;VALUE=DATE:20291008
SUMMARY:Letrozole: Phase 2 readout est. (NCT04557449)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Study to Test the Safety and Tolerability of PF-07220060 in Participant
 s With Advance Solid Tumors\nEstimated primary completion: 7 October 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04557449
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120283-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Letrozole: Phase 1 readout est. (NCT06120283)
DESCRIPTION:Letrozole\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: BGB-43395 Alone or as Part of Combination Therapies in Participants Wit
 h Breast Cancer and Other Advanced Solid Tumors\nEstimated primary complet
 ion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/l
 etrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06120283
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Letrozole: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Compa
 red With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in H
 R-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\, 
 BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 18
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letro
 zole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06380751
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05226871-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Letrozole: Phase 2 readout est. (NCT05226871)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Study for Participants Continuing From Pfizer-sponsored Palbociclib (a 
 Study Medicine) Studies\nEstimated primary completion: 31 December 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05226871
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645536-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Letrozole: Phase 3 readout est. (NCT05645536)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Safety Extension Study for Subjects With HR+\, HER2- Breast Cancer for 
 Subjects Who Have Completed the OVELIA Study\nEstimated primary completion
 : March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozo
 le#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5645536
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897721-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300322
DTEND;VALUE=DATE:20300323
SUMMARY:Letrozole: Phase 1 readout est. (NCT07897721)
DESCRIPTION:Letrozole\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Study to Learn About the Study Medicine Called PF-08165784 in People 
 With PIK3CA-Mutated Advanced or Metastatic Solid Tumors\nEstimated primary
  completion: 22 March 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07897721
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05161195-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Letrozole: Phase 4 readout est. (NCT05161195)
DESCRIPTION:Letrozole\, phase 4\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Roll-over Study to Allow Continued Access to Ribociclib\nEstimated prim
 ary completion: 28 June 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05161195
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Co
 mbination With Other Antineoplastic Agents in Participants With Advanced S
 olid Tumors\nEstimated primary completion: July 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867262-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300815
DTEND;VALUE=DATE:20300816
SUMMARY:Letrozole: Phase 1 readout est. (NCT07867262)
DESCRIPTION:Letrozole\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozo
 le\, Fulvestrant\, or Giredestrant in Participants With Locally Advanced o
 r Metastatic Hormone Receptor-Positive\, HER2-Negatve Breast Cancer\nEstim
 ated primary completion: 15 August 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07867262
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716046-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Letrozole: Phase 2 readout est. (NCT07716046)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HE
 R2+ Advanced Breast Cancer\nEstimated primary completion: 31 August 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07716046
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953882-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Letrozole: Phase 2 readout est. (NCT06953882)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Impact of Omitting Chemo Based on Patient's Selection for ER-Positive\,
  HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy\nEstima
 ted primary completion: September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06953882
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Study Evaluating the Efficacy and Safety of Multiple Treatment Comb
 inations in Patients With Metastatic or Locally Advanced Breast Cancer\nEs
 timated primary completion: 30 September 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Letrozole: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Letrozole\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuvant and Perso
 nalized Adaptive Novel Agents to Treat Breast Cancer\nEstimated primary co
 mpletion: December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT01042379
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04852887-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20310408
DTEND;VALUE=DATE:20310409
SUMMARY:Letrozole: Phase 3 readout est. (NCT04852887)
DESCRIPTION:Letrozole\, phase 3.\nStudy: De-Escalation of Breast Radiation 
 Trial for Hormone Sensitive\, HER-2 Negative\, Oncotype Recurrence Score L
 ess Than or Equal to 18 Breast Cancer (DEBRA)\nEstimated primary completio
 n: 8 April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letr
 ozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04852887
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288359-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20310509
DTEND;VALUE=DATE:20310510
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT07288359)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of GVV858 as a Single Agent or in Combination With Endocrine Th
 erapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tu
 mors\nEstimated primary completion: 9 May 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07288359
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07894328-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20310730
DTEND;VALUE=DATE:20310731
SUMMARY:Letrozole: Phase 3 readout est. (NCT07894328)
DESCRIPTION:Letrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line The
 rapy in Patients With Advanced or Metastatic Breast Cancer\nEstimated prim
 ary completion: 30 July 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/letrozole#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07894328
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101159-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Letrozole: Phase 2 readout est. (NCT07101159)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Dalpiciclib as Adjuvant Therapy fo
 r HR-positive/HER2-negative Early-stage Patients\nEstimated primary comple
 tion: December 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07101159
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581834-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Letrozole: Phase 2 readout est. (NCT07581834)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Efficacy and Safety of Dalpiciclib
  Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Canc
 er: a Multicenter\, Prospective Clinical Study\nEstimated primary completi
 on: 31 December 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /letrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07581834
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679269-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20320323
DTEND;VALUE=DATE:20320324
SUMMARY:Letrozole: Phase 2 readout est. (NCT07679269)
DESCRIPTION:Letrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Ter
 m Safety.\nEstimated primary completion: 23 March 2032. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07679269
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06223698-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20320502
DTEND;VALUE=DATE:20320503
SUMMARY:Letrozole: Phase 3 readout est. (NCT06223698)
DESCRIPTION:Letrozole\, phase 3.\nStudy: Optimizing Extended Adjuvant Endoc
 rine Therapy in Patients With Breast Cancer\nEstimated primary completion:
  2 May 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozol
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 223698
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604571-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20320608
DTEND;VALUE=DATE:20320609
SUMMARY:Letrozole: Phase 1 readout est. (NCT07604571)
DESCRIPTION:Letrozole\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Study of IEV407 as Single Agent or in Combination in Patients With Adva
 nced HR+/HER2- Breast Cancer\nEstimated primary completion: 8 June 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/letrozole#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07604571
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07866430-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20321031
DTEND;VALUE=DATE:20321101
SUMMARY:Letrozole: Phase 2 readout est. (NCT07866430)
DESCRIPTION:Letrozole\, phase 2.\nStudy: De-EscaLaTion of Aromatase Inhibit
 or Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormo
 ne Receptor-Positive Early Breast Cancer\nEstimated primary completion: Oc
 tober 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/letrozole
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 66430
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348134-9035@assetmemo.bio
DTSTAMP:20261121T004044Z
DTSTART;VALUE=DATE:20340701
DTEND;VALUE=DATE:20340702
SUMMARY:Letrozole: Phase 2 readout est. (NCT06348134)
DESCRIPTION:Letrozole\, phase 2.\nStudy: Assessing the Efficacy and Safety 
 of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and
  After Surgery\nEstimated primary completion: 1 July 2034. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06348134
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
